90513-12-5

Usage

Chemical compound

4-(2-aminoethyl)Benzamide

Derivative of

Benzamide

Contains

Aminoethyl group

Used in pharmaceutical research for

Potential treatment for conditions such as cancer, inflammation, and central nervous system disorders

Studied for its ability to

Inhibit enzymes and receptors involved in disease development and progression

Investigated for potential use as

Fluorescent probe for detecting and imaging specific biomolecules in biological systems
Shows promise in research areas for potential therapeutic and diagnostic applications

Upstream product

• 177736-05-9 4-[2-(t-butoxycarbonylamino)ethyl]benzamide 
• 177736-04-8 methyl 4-[2-(tert-butoxycarbonylamino)ethyl]benzoate 
• 56161-89-8 4-(2-aminoethyl)-benzoic acid methyl ester-hydrochloride 
• 167762-80-3 4‐(2‐aminoethyl)benzonitrile hydrochloride 
• 69395-13-7 4-(2-hydroxyethyl)benzonitrile 
• 714568-47-5 4-(2-azidoethyl)benzonitrile 

Relevant academic research and scientific papers

Synthesis and study of new quinolineaminoethanols as anti-bacterial drugs

The lack of antibiotics with a novel mode of action associated with the spread of drug resistant bacteria make the fight against infectious diseases particularly challenging. A quinoline core is found in several anti-infectious drugs, such as mefloquine and bedaquiline. Two main objectives were set in this work. Firstly, we evaluated the anti-mycobacterial properties of the previous quinolines 3, which have been identified as good candidates against ESKAPEE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter spp. and Escherichia coli) bacteria. Secondly, a new series 4 was designed and assessed against the same bacteria strains, taking the pair of enantiomers 3m/3n as the lead. More than twenty compounds 4 were prepared through a five-step asymmetric synthesis with good enantiomeric excesses (>90%). Interestingly, all compounds of series 3 were efficient on M. avium with MIC = 2–16 μg/mL, while series 4 was less active. Both series 3 and 4 were generally more active than mefloquine against the ESKAPEE bacteria. The quinolines 4 were either active against Gram-positive bacteria (MIC ≤ 4 μg/mL for 4c–4h and 4k/4l) or E. coli (MIC = 32–64 μg/mL for 4q–4v) according to the global lipophilicity of these compounds.

Design and Synthesis of New 1,3,5-Trisubstituted Triazines for the Treatment of Cancer and Inflammation

Low-molecular-weight synthetic molecules 1 with the general 2-(fluorophenylamino)-4,6-disubstituted 1,3,5-triazine structure and showing anti-inflammatory and anticancer activities were explored. Structure–activity relationship studies demonstrated the importance of the aminopentyl chain, the 3- or 4-fluorophenylaniline component, and the presence of at least one substituent, such as a tyramine moiety, attached directly to the triazine ring as essential for good activity. These compounds, represented by leads 4-{2-[4-(5-Aminopentylamino)-6-(3-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (6) and 4-{2-[4-(5-Aminopentylamino)-6-(4-fluorophenylamino)-1,3,5-triazin-2-ylamino]ethyl}phenol (10), displayed moderate and significant in vitro and in vivo dual activities, respectively, and address the molecular link between inflammation and cancer. Compound 10 demonstrated significant antitumor efficacy upon administration by the oral and intravenous routes in several animal models. This class of triazine compounds is new, safe, and nontoxic and offers a novel approach to the treatment of inflammation and cancer.

"TRIAZINE DERIVATIVES, COMPOSITIONS CONTAINING SUCH DERIVATIVES, AND METHODS OF TREATMENT OF CANCER AND AUTOIMMUNE DISEASES USING SUCH DERIVATIVES"

We describe compounds of the following general formula (I): wherein X is fluorine or chlorine; Y is oxygen, sulfur, or an amino group; R is an amino, hydroxyl, sulfonamide, or carboxamide group or an N-monomethyl or N-dimethyl analog thereof; m is an integer from 2 to 6, and n is an integer from 0 to 2. The compounds may be used for treating certain cancers and autoimmune diseases.

2-QUINOXALINONE DERIVATIVES AS BRADYKININ ANTAGONISTS AND NOVEL COMPOUNDS

2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

NOVEL QUINOXALINONE DERIVATIVES AS BRADYKININ B1 ANTAGONISTS

2-Quinoxalinone derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway.

Novel phenethanolamines

The tertiary amines of the formula STR1 wherein n represents a whole number of 1 to 5; X1 represents phenyl or phenyl mono-, di- or tri-substituted by R1, R2 and R3 ; X2 represents hydrogen, lower-alkyl, phenyl or phenyl mono-, di- or tri-substituted by R1, R2 and R3 ; Y represents hydrogen, lower-alkyl, hydroxymethyl, carboxy or lower-alkoxycarbonyl; Z represents a group of the formula STR2 R1, R2 and R3 represent hydrogen, halogen, hydroxy, benzyloxy, lower-alkyl, lower-alkoxy, hydroxymethyl, amino, acylamino, lower-alkoxybenzylamino, nitro, carbamoyl, trifluoromethyl or lower-alkylsulphonylmethyl; R4, R5 and R51 represent hydrogen, lower-alkyl, lower-alkoxy, lower alkanoyl, carboxy, cyano, hydroxy, hydroxy-lower-alkyl, acyloxy or a group --C(R6)=C(R7)COOR8, --SO2 R9, --C(O)R9 or --CH2 R10, with the proviso that R4 does not represent hydrogen when R5 represents hydroxy, lower-alkyl or lower-alkoxy; R6, R7 and R8 represent hydrogen or lower-alkyl; R9 represents amino, mono-lower-alkylamino or a group R; R represents di-lower-alkylamino, piperidino, morpholino, thiamorpholino, piperazino or the ether group of a lower aliphatic, cycloaliphatic or araliphatic alcohol or of a phenol; and R10 represents a group R and, where R1, R2 and R3 represent hydrogen, halogen, hydroxy, benzyloxy, lower-alkyl, lower-alkoxy, hydroxymethyl, amino, lower-alkoxybenzylamino or trifluoromethyl and simultaneously Y represents hydrogen, lower-alkyl or hydroxymethyl, R10 can also represent amino or mono-lower-alkylamino, have hypoglycaemic activity and reduce glycosuria. They are manufactured from corresponding primary or secondary amines.